BriaCell Therapeutics Corp. (BCTXW)
USD 0.1
(-1.67%)
USD 0.1
(-1.67%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -24.12 Million | -23.74 Million | -12.48 Million | -7.74 Million | -1.15 Million | -3.87 Million |
| Net Income | -4.93 Million | -20.3 Million | -26.83 Million | -428.33 Thousand | -3.68 Million | -4.4 Million |
| Depreciation & Amortization | 83.89 Thousand | 15.27 Thousand | 15.27 Thousand | 15.25 Thousand | 13.96 Thousand | 14.25 Thousand |
| Deferred income taxes | - | -1.04 Million | 11.65 Million | -8.86 Million | - | 1.03 |
| Stock-based compensation | 1.8 Million | 2.19 Million | 3.07 Million | 1.96 Million | 1686.00 | 46.07 Thousand |
| Change in working capital | 7.05 Million | -3.53 Million | -391.29 Thousand | -2.28 Million | 2.44 Million | 787.89 Thousand |
| Other non-cash items | -28.13 Million | -1.07 Million | -2409.00 | 1.84 Million | 64.65 Thousand | -319.85 Thousand |
| Investing Cash Flow | -681.8 Thousand | - | - | - | - | 1.01 Million |
| Investments in PPE | -456.8 Thousand | - | - | - | - | - |
| Acquisitions | -225 Thousand | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -225 Thousand | - | - | - | - | - |
| Financing Cash Flow | 4.41 Million | 3.95 Million | -3.74 Million | 64.99 Million | 1.07 Million | 2.27 Million |
| Debt repayment | - | - | - | -548.64 Thousand | -355.97 Thousand | -95.67 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -47.29 Thousand | -10.17 Million | - | - | - |
| Common Stock Issuance | 4.41 Million | 4 Million | - | 51.62 Million | 1.05 Million | 2.26 Million |
| Other Financing Activities | 4.41 Million | 1594.00 | 6.42 Million | 13.92 Million | 376.54 Thousand | 17.08 Thousand |
| Accounts receivables | -732.57 Thousand | 5230.00 | - | - | - | - |
| Accounts payables | 6.04 Million | 660.45 Thousand | 249.16 Thousand | -1.4 Million | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.73 Million | -4.19 Million | -640.45 Thousand | -876.44 Thousand | - | 787.89 Thousand |
| Cash at beginning of period | 21.25 Million | 41.04 Million | 57.26 Million | 21.24 Thousand | 143.79 Thousand | 713.69 Thousand |
| Cash at end of period | 862.08 Thousand | 21.25 Million | 41.04 Million | 57.26 Million | 19.45 Thousand | 146.71 Thousand |
| Capital Expenditure | -456.8 Thousand | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | -40.24 Thousand | 9533.66 |
| Net cash flow / Change in cash | -20.38 Million | -19.79 Million | -16.22 Million | 57.24 Million | -124.34 Thousand | -566.97 Thousand |
| Free Cash Flow | -24.58 Million | -23.74 Million | -12.48 Million | -7.74 Million | -1.15 Million | -3.87 Million |
| Breakdown | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.24 Million | 1.69 Million | -11.33 Million | 5.95 Million | -2.41 Million | -20.3 Million |
| Depreciation & Amortization | 72.44 Thousand | 3816.00 | 3819.00 | 3818.00 | 3818.00 | 15.27 Thousand |
| Deferred income taxes | -689.82 Thousand | - | - | 689.82 Thousand | - | -1.04 Million |
| Stock-based compensation | 377.89 Thousand | 392.21 Thousand | 500.15 Thousand | 533.81 Thousand | 533.81 Thousand | 2.19 Million |
| Change in working capital | 1.29 Million | 3.73 Million | 1.84 Million | 180.32 Thousand | -3.94 Million | -3.53 Million |
| Other non-cash items | -4.53 Million | -10.9 Million | 1.58 Million | -14.97 Million | -5.09 Million | -1.07 Million |
| Investing Cash Flow | -456.8 Thousand | -225 Thousand | - | - | - | - |
| Investments in PPE | -456.8 Thousand | - | - | - | - | - |
| Acquisitions | 225 Thousand | -225 Thousand | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -456.8 Thousand | - | - | - | - | - |
| Financing Cash Flow | 4.41 Million | - | - | - | 4 Million | 3.95 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | 47.29 Thousand | -47.29 Thousand |
| Common Stock Issuance | - | - | - | - | - | 4 Million |
| Other Financing Activities | 4.41 Million | - | - | - | 3.95 Million | 1594.00 |
| Accounts receivables | -736.21 Thousand | 14.91 Thousand | - | - | - | - |
| Accounts payables | 748.37 Thousand | 2.71 Million | 3.27 Million | -689.82 Thousand | 128.48 Thousand | 660.45 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.28 Million | 1.01 Million | -1.43 Million | 689.82 Thousand | -4.07 Million | -4.19 Million |
| Cash at beginning of period | 935.69 Thousand | 6.24 Million | 13.64 Million | 21.25 Million | 28.17 Million | 41.04 Million |
| Cash at end of period | 862.08 Thousand | 935.69 Thousand | 6.24 Million | 13.64 Million | 21.25 Million | 21.25 Million |
| Capital Expenditure | -456.8 Thousand | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -73.6 Thousand | -5.3 Million | -7.4 Million | -7.6 Million | -6.91 Million | -19.79 Million |
| Free Cash Flow | -4.49 Million | -5.08 Million | -7.4 Million | -7.6 Million | -10.91 Million | -23.74 Million |
VLTTF
CLE
IPH
VIKASLIFE
IPG
AGNCL